Procter & Gamble Hygiene & Health Care Ltd. (PGHH) AI Stock Analysis

• Market Cap: ₹330.14B
• Dividend Yield: 2.08%
• Average Volume (3M): 854.00
• Price to Earnings (P/E): 54.7
• Beta (1Y): 0.42
• Revenue Growth: 8.28%
• EPS Growth: 11.65%
• Country: IN
• Employees: 439
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): N/A
• Shares Outstanding: 32,460,735
• 10 Day Avg. Volume: 1,521
• 30 Day Avg. Volume: 854
• PEG Ratio: 2.02
• Price to Book (P/B): 59.85
• Price to Sales (P/S): 9.80
• P/FCF Ratio: 78.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 272.53
• Revenue Forecast (FY): ₹44.41B

• Rating: 63 Neutral
• Price Target: ₹10,669.00 ▼(-15.96% Downside)
• Action: Reiterated Date: 10/25/25
• Date: Action: Reiterated 10/25/25

Procter & Gamble Hygiene & Health Care Ltd. demonstrates strong financial performance with consistent growth and profitability, which is the most significant factor in its overall score. The technical analysis indicates a bearish trend, and the valuation suggests the stock may be overvalued, slightly offsetting the strong financials. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strong profitability & margins

High and stable gross, EBIT and net margins indicate durable profitability and operational discipline. Sustained margins in FMCG support reinvestment in brands, pricing power and cash generation, underpinning long-term ability to fund growth and shareholder returns.

Low leverage / solid capital structure

Very low debt-to-equity and a healthy equity ratio provide financial flexibility to fund marketing, innovation and distribution without heavy refinancing risk. Minimal leverage reduces interest burden and supports resilience through demand cyclicality common in consumer staples.

Strong free cash flow generation

Positive trend in free cash flow and strong operating cash flow conversion show the business converts earnings into cash reliably. Robust cash generation funds capex, brand investment and dividends, reducing reliance on external financing for strategic initiatives.

Negative Factors

Recent revenue contraction

A near -44% revenue growth metric signals material top-line contraction that could reflect volume loss, pricing pressure or portfolio shifts. Even with good margins, sustained revenue declines erode operating leverage and limit long-term profit growth unless reversed.

Decrease in shareholders' equity

The noted slight decrease in stockholders' equity implies retention or capital erosion issues which can constrain capital allocation over time. Persistent equity declines reduce buffer against losses, limit debt capacity if liquidity needs arise, and may indicate payout or accounting pressures.

Dependence on P&G group association

Reliance on the Procter & Gamble group's brand equity and supply-chain know-how is strategic, but unspecified partnership terms create related-party and governance risk. Unclear royalties, sourcing or licensing obligations could structurally affect margins and operational autonomy.

Procter & Gamble Hygiene & Health Care Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. The company provides health care products, including ointments and creams, cough drops, and tablets; and hygiene products, such as feminine hygiene and other skin care hygiene products, as well as feminine care pads. It also offers baby care products comprising nappies, pants, and baby wipes; laundry products; hair care products; home care products; and oral care products. The company offers its products under the Vicks, Whisper, Pampers, Ariel, Tide, Gillette, Head & Shoulders, Herbal Essences, Pantene, Ambi Pur, Oral-B, Olay, and Old Spice brand names. It sells its products through retail operations, including mass merchandisers, as well as grocery, membership club, drug, department, and high frequency stores. The company was incorporated in 1964 and is based in Mumbai, India. Procter & Gamble Hygiene and Health Care Limited is a subsidiary of Procter & Gamble Overseas India BV.

How the Company Makes Money

PGHH primarily makes money by selling branded consumer health and hygiene products in India. Its core revenue model is volume- and brand-led FMCG sales: products are manufactured and/or sourced, then sold to trade customers (distributors/wholesalers/modern retail), pharmacies, and other retail channels for resale to end consumers. Key revenue streams are (1) oral care products (e.g., toothpastes and related oral hygiene items) and (2) feminine hygiene products (e.g., sanitary protection). Earnings are driven by a mix of unit volumes, pricing, product mix (premium vs. value variants), and brand investment that supports repeat purchase and market share. The company’s go-to-market relies on wide distribution and retail availability across general trade and modern trade; where applicable for OTC health products, pharmacy/chemist channel presence also supports sales. A significant factor influencing how PGHH earns is its association with the Procter & Gamble group’s brand equity, product know-how, and supply chain capabilities; however, specific partnership terms (e.g., royalties, technical service arrangements, or related-party sourcing details) are null.

Procter & Gamble Hygiene & Health Care Ltd. Financial Statement Overview

Summary

Procter & Gamble Hygiene & Health Care Ltd. exhibits a strong financial position across all verticals. The income statement reflects consistent growth and profitability, the balance sheet indicates financial stability with low leverage, and the cash flow statement shows strong cash generation capabilities. The company is well-positioned to sustain its growth trajectory and manage potential risks effectively.

Income Statement

Procter & Gamble Hygiene & Health Care Ltd. demonstrates strong financial performance with consistent revenue growth and healthy profit margins. The gross profit margin remains robust, indicating efficient cost management, while the net profit margin shows solid profitability. The EBIT and EBITDA margins are stable, reflecting effective operational management. Overall, the income statement reflects a positive growth trajectory and profitability.

Balance Sheet

The company's balance sheet is characterized by a very low debt-to-equity ratio, indicating minimal leverage and financial stability. The return on equity is strong, showcasing effective utilization of shareholder funds to generate profits. The equity ratio is healthy, suggesting a solid capital structure. However, a slight decrease in stockholders' equity over the years could be a point of concern.

Cash Flow

The cash flow statement reveals a positive trend in free cash flow growth, indicating strong cash generation capabilities. The operating cash flow to net income ratio is healthy, suggesting efficient conversion of income into cash. The free cash flow to net income ratio is also strong, reflecting the company's ability to generate cash relative to its net income. Overall, the cash flow position is robust, supporting the company's operational and strategic initiatives.

Breakdown	TTM	Mar 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	44.99B	44.99B	42.06B	39.05B	39.01B	35.70B
Gross Profit	25.48B	25.48B	25.76B	22.42B	17.17B	22.42B
EBITDA	12.11B	12.11B	10.22B	8.98B	8.43B	9.18B
Net Income	8.49B	8.49B	6.75B	6.78B	5.76B	6.52B
Balance Sheet
Total Assets	17.55B	17.55B	18.59B	21.37B	16.81B	16.33B
Cash, Cash Equivalents and Short-Term Investments	5.16B	5.16B	5.74B	9.64B	6.25B	6.48B
Total Debt	23.20M	23.20M	30.80M	40.30M	51.00M	34.70M
Total Liabilities	10.18B	10.18B	10.84B	11.91B	9.44B	9.18B
Stockholders Equity	7.37B	7.37B	7.75B	9.46B	7.38B	7.14B
Cash Flow
Free Cash Flow	5.63B	5.63B	4.26B	7.81B	5.23B	8.32B
Operating Cash Flow	6.18B	6.18B	4.71B	8.26B	5.73B	8.63B
Investing Cash Flow	-586.30M	-586.30M	10.60M	-99.10M	-268.50M	69.40M
Financing Cash Flow	-6.66B	-6.66B	-8.62B	-4.77B	-5.69B	-11.06B

Procter & Gamble Hygiene & Health Care Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12694.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHH, the sentiment is Negative. The current price of 12694.65 is above the 20-day moving average (MA) of 11081.00, above the 50-day MA of 11627.71, and below the 200-day MA of 12716.85, indicating a bearish trend. The MACD of -391.37 indicates Positive momentum. The RSI at 16.24 is Positive, neither overbought nor oversold. The STOCH value of 3.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PGHH.

Procter & Gamble Hygiene & Health Care Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COLPAL	70 Outperform	₹527.64B	43.58	―	2.42%	-2.06%	-9.74%
DABUR	66 Neutral	₹813.33B	39.88	―	1.62%	2.68%	1.07%
ZYDUSWELL	66 Neutral	₹134.92B	-90.62	―	0.28%	14.55%	-20.61%
EMAMILTD	64 Neutral	₹186.13B	18.06	―	1.91%	0.84%	-2.44%
PGHH	63 Neutral	₹330.14B	54.70	―	2.08%	8.28%	11.65%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
GILLETTE	56 Neutral	₹258.24B	39.50	―	1.39%	7.42%	22.99%

Procter & Gamble Hygiene & Health Care Ltd. Corporate Events

P&G Hygiene & Health Care Declares Rs 195 Interim Dividend, Details TDS Rules for FY 2025-26

Procter & Gamble Hygiene and Health Care Limited’s board has declared an interim dividend of Rs 195 per equity share for FY 2025-26, which includes a one-time special dividend of Rs 25 per share, payable to shareholders on record as of February 5, 2026. In line with post-2020 tax rules that make dividends taxable in the hands of shareholders, the company has outlined applicable TDS provisions for resident investors and urged both demat and physical shareholders to update PAN, tax residency and contact details with depositories or the registrar so that the correct tax deduction at source rate can be applied, thereby affecting net dividend payouts and compliance requirements for investors.